Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | KARS1 | Q15046 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 10/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21209364 | 0.89 | DRD1 (0.41) | CSNK1ENMT1 | |
| SCHEMBL21209380 | 0.87 | KDM4E (0.47) | — | |
| SCHEMBL21208129 | 0.85 | CSNK1E (0.47) | CSNK1EKARS1DYRK1ANMT1TLR9 | |
| SCHEMBL21211450 | 0.83 | CYP1A2 (0.51) | CSNK1E | |
| SCHEMBL21209777 | 0.81 | CSNK1E (0.47) | CSNK1EKARS1 | |
| SCHEMBL24688736 | 0.76 | CSNK1E (0.56) | CSNK1EKARS1DYRK1ANMT1TLR9 | |
| SCHEMBL21208130 | 0.74 | CDK2 (0.48) | NMT1 | |
| SCHEMBL21217063 | 0.72 | PRKDC (0.52) | CSNK1E | |
| SCHEMBL21208646 | 0.71 | ALDH1A1 (0.42) | — | |
| SCHEMBL21208926 | 0.70 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | CSNK1E 431/4885KARS1 1965/4885DYRK1A 1956/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CSNK1E 1424/4885KARS1 2649/4885DYRK1A 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.